FDA Approves Lilly's Selpercatinib for RET-Driven Solid Tumors
LLY sits 85% above its 52-week low of $623.78.
Summary
The FDA granted traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors, expanding the drug's label beyond its prior accelerated approvals in lung and thyroid cancers. This marks a significant regulatory win for Lilly's oncology portfolio, adding a tumor-agnostic indication that could meaningfully broaden the addressable patient population. The approval follows a series of positive pipeline developments for Lilly, including recent late-stage wins for its obesity and diabetes franchises. With a market cap over $1 trillion, the direct financial impact may be modest relative to Lilly's GLP-1 blockbusters, but it reinforces the company's diversification into high-value oncology. No specific upcoming catalysts were mentioned.
At the time of this announcement, LLY was trading at $1,154.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.